Pharmacovigilance Regulatory Timelines Explained: Day 0, Day 7, Day 15, and Day 90 Reporting
Pharmacovigilance regulatory timelines define how quickly adverse drug reactions must be reported to health authorities after they are identified. These timelines ensure that important safety information about medicines is communicated promptly, allowing regulators to assess risks and protect patient safety.
In pharmacovigilance, reporting timelines are calculated from Day 0, which is the date when a valid Individual Case Safety Report (ICSR) is first received by the pharmacovigilance system. The most common reporting milestones include Day 7, Day 15, and Day 90.
Day0– Start of Pharmacovigilance Reporting
Day 0 is the official beginning of all pharmacovigilance reporting timelines. It is the day on which the pharmacovigilance system receives a valid Individual Case Safety Report (ICSR) or when an adverse event is first detected. (ICH E2A guideline).
A valid ICSR contains the minimum required information, which includes
- an identifiable patient,
- an identifiable reporter,
- a suspect medicinal product, and
- suspected adverse reaction
Definition: Within seven calendar days of Day 0, the initial report for a fatal or life-threatening Suspected Unexpected Serious Adverse Reaction (SUSAR) must be sent to the relevant health authorities.
If more information later becomes available, it must be submitted within eight more calendar days following the original submission.(EMA GVP Module VI) Day 15 – Non‑Fatal SUSARs / Serious Adverse Events (SAEs)
Definition: Regulatory authorities must receive reports of non-fatal SUSARs and other serious adverse events within 15 calendar days of Day 0. This schedule guarantees that significant safety issues are promptly reported for assessment and regulatory action.(PvPI/CDSCO Guidance, India) Day 90 – Non‑Serious Adverse Events / Follow‑Up
Definition: Within 90 calendar days of Day 0, non-serious adverse events and follow-up data for previously reported cases are often submitted. This period offers a consistent timescale for routine case reporting and data completeness, even though it is not included in the expedited reporting requirements for serious incidents.(ICH E2C(R2) – PSUR/PBRER) Periodic Reports (PSUR / PBRER)
The purpose of Periodic Safety Update Reports (PSURs) and Periodic Benefit-Risk Evaluation Reports (PBRERs) is to provide an organized assessment of all accumulated safety data, emerging risks, and the benefit-risk balance of a medicinal product at predetermined intervals (e.g., quarterly, semi-annual, or annual). Regulatory evaluation and continuous risk management are supported by these reports.
|
Timeline
|
Reporting Requirement
|
|
Day 0
|
Date when
a valid ICSR is received
|
|
Day 7
|
Fatal or
life-threatening SUSAR initial report
|
|
Day 15
|
Non-fatal
SUSAR or serious adverse events
|
|
Day 90
|
Non-serious
adverse events and follow-up data
|
👉Pharmacovigilance regulatory timelines play a critical role in ensuring timely reporting of adverse drug reactions to health authorities. The key milestones—Day 0, Day 7, Day 15, and Day 90—help standardize safety reporting and allow regulators to monitor medicine safety effectively. Understanding these timelines is essential for professionals working in pharmacovigilance, drug safety, and regulatory affairs.
Frequently Asked Questions (FAQs)
1. What is Day 0 in pharmacovigilance?
Day 0 is the date when a valid Individual Case Safety Report (ICSR) is first received by the pharmacovigilance system.
2. What is the reporting timeline for fatal SUSAR?
Fatal or life-threatening SUSARs must be reported within 7 calendar days.
3. What is the reporting timeline for non-fatal SUSAR?
Non-fatal SUSARs must be reported within 15 calendar days from Day 0.
Call-to-Action: Did you find this blog helpful? Share your thoughts in the comments below.
.png)
Comments
Post a Comment